Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults
Primary Purpose
Diarrhea
Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Probiotic: Bio-K+ CL1285
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Diarrhea focused on measuring Bio-K+CL1285, Probiotics, Traveler's Diarrhea, Lactobacillus Acidophilus, Lactobacillus Casei
Eligibility Criteria
Inclusion Criteria:
- Male or female subjects over 18 years of age traveling to Mexico, Central America, South America and Caribbean Islands as direct destinations or on cruises to the same destinations.
- The trips last a minimum of 7 days and a maximum of 21 days.
- Women of child bearing capacity who are not pregnant at the moment of screening (pregnancy test done on-site) and agree to use an acceptable form of birth control for the duration of the study (e.g. Condom, oral contraceptives, etc.) are allowed to participate.
Exclusion Criteria:
- active diarrhea;
- pregnancy; breastfeeding
- 3 diarrheic episodes within 24 hours in the 15 days preceding the date of the departure;
- antibiotic treatment during the last 15 days or ongoing treatment at the time of departure;
- consumption of fermented milk, yogourt or probiotics probiotics in the 15 days preceding the date of the departure;
- immunosuppressed state or any health condition being susceptible to decompensate during the study (including malignant hemo-pathologies, AIDS, bone marrow transplant or organ transplant).
- active radiotherapy or chemotherapy as cancer treatment
- the administration of an ETEC/cholera vaccine or any other diarrhea vaccine in the three months prior to study initiation
- an active, non-controlled intestinal disease;
- ileostomy, jejunostomy or colostomy
- concomitant participation in another clinical trial
- mental or other conditions, or language barriers rendering the subject unable to understand the nature, scope, and possible consequences of the study or complete the self-administered questionnaires;
- subject unlikely to comply with protocol, e.g., uncooperative attitude, and unlikelihood of completing the study,
- allergies to any ingredients in the study product (active product or placebo)
- current use of illicit drug and alcohol abuse
Sites / Locations
- Clinique Santé Voyage des Prairies
- Clinique Santé Voyage de Laval
- Clinique Santé Voyage Saint-Luc
- Sant Voyage Medisys
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
The probiotic Bio-K+ CL1285 RX®
Placebo
Outcomes
Primary Outcome Measures
To determine the efficacy of Bio-K+ CL1285 RX® in reducing traveler's diarrhea by comparing the incidence of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX® or placebo prophylaxis.
Secondary Outcome Measures
To compare the severity of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX® or placebo prophylaxis.
To compare the safety profile of BIO-K+CL1285 RX® to that of placebo
To compare the physician and traveler satisfaction following daily prophylaxis with either BIO-K+CL1285 RX® or placebo
To evaluate and compare the health economic impact of daily prophylaxis with BIO-K+CL1285 RX®.
Full Information
NCT ID
NCT00737412
First Posted
August 15, 2008
Last Updated
January 19, 2010
Sponsor
Bio-K Plus International Inc.
Collaborators
ethica Clinical Research Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00737412
Brief Title
Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults
Official Title
A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2010
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
January 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Bio-K Plus International Inc.
Collaborators
ethica Clinical Research Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine the efficacy of Bio-K+ CL1285 in reducing traveler's diarrhea.
Detailed Description
Determine efficacy of Bio-K+ CL1285 in reducing Traveler's Diarrhea by comparing the incidence of diarrhea in travelers during their stay abroad and upon their return to Canada following either Bio-K+ CL-1285 OR placebo prophylaxis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diarrhea
Keywords
Bio-K+CL1285, Probiotics, Traveler's Diarrhea, Lactobacillus Acidophilus, Lactobacillus Casei
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
277 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
The probiotic Bio-K+ CL1285 RX®
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Other
Intervention Name(s)
Probiotic: Bio-K+ CL1285
Other Intervention Name(s)
Bio-K+ CL1285 RX®
Intervention Description
The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Matching capsules devoid of microorganisms
Primary Outcome Measure Information:
Title
To determine the efficacy of Bio-K+ CL1285 RX® in reducing traveler's diarrhea by comparing the incidence of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX® or placebo prophylaxis.
Time Frame
March 2008 to April 2009
Secondary Outcome Measure Information:
Title
To compare the severity of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX® or placebo prophylaxis.
Time Frame
March 2008 to April 2009
Title
To compare the safety profile of BIO-K+CL1285 RX® to that of placebo
Time Frame
March 2008 to April 2009
Title
To compare the physician and traveler satisfaction following daily prophylaxis with either BIO-K+CL1285 RX® or placebo
Time Frame
March 08 to April 09
Title
To evaluate and compare the health economic impact of daily prophylaxis with BIO-K+CL1285 RX®.
Time Frame
March 08 to April 09
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female subjects over 18 years of age traveling to Mexico, Central America, South America and Caribbean Islands as direct destinations or on cruises to the same destinations.
The trips last a minimum of 7 days and a maximum of 21 days.
Women of child bearing capacity who are not pregnant at the moment of screening (pregnancy test done on-site) and agree to use an acceptable form of birth control for the duration of the study (e.g. Condom, oral contraceptives, etc.) are allowed to participate.
Exclusion Criteria:
active diarrhea;
pregnancy; breastfeeding
3 diarrheic episodes within 24 hours in the 15 days preceding the date of the departure;
antibiotic treatment during the last 15 days or ongoing treatment at the time of departure;
consumption of fermented milk, yogourt or probiotics probiotics in the 15 days preceding the date of the departure;
immunosuppressed state or any health condition being susceptible to decompensate during the study (including malignant hemo-pathologies, AIDS, bone marrow transplant or organ transplant).
active radiotherapy or chemotherapy as cancer treatment
the administration of an ETEC/cholera vaccine or any other diarrhea vaccine in the three months prior to study initiation
an active, non-controlled intestinal disease;
ileostomy, jejunostomy or colostomy
concomitant participation in another clinical trial
mental or other conditions, or language barriers rendering the subject unable to understand the nature, scope, and possible consequences of the study or complete the self-administered questionnaires;
subject unlikely to comply with protocol, e.g., uncooperative attitude, and unlikelihood of completing the study,
allergies to any ingredients in the study product (active product or placebo)
current use of illicit drug and alcohol abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominique Tessier, MD
Organizational Affiliation
Sante Voyage Medisys
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Benoit Brizard, MD
Organizational Affiliation
Clinique Santé Voyage de Laval
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Benoit Cote, MD
Organizational Affiliation
Clinique Sante Voyage des Prairies
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jean Vincelette, MD
Organizational Affiliation
Sante Voyage Saint-Luc
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinique Santé Voyage des Prairies
City
Joliette
State/Province
Quebec
ZIP/Postal Code
J6E 1G2
Country
Canada
Facility Name
Clinique Santé Voyage de Laval
City
Laval
State/Province
Quebec
ZIP/Postal Code
H7G2E6
Country
Canada
Facility Name
Clinique Santé Voyage Saint-Luc
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2X 2H9
Country
Canada
Facility Name
Sant Voyage Medisys
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 3C6
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults
We'll reach out to this number within 24 hrs